clinical development raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
It is noteworthy that the genetic code for all organisms is basically the same, so that all living beings use the same 'genetic language'. In general, the introduction of new functional unnatural amino acids into proteins of living cells breaks the universality of the genetic language, which ideally leads to alternative life forms. Proteins are produced thanks to the translational system molecules, which decode the RNA messages into a string of amino acids. The translation of genetic information contained in messenger RNA (mRNA) into a protein is catalysed by ribosomes. Transfer RNAs (tRNA) are used as keys to decode the mRNA into its encoded polypeptide. The tRNA recognizes a specific three nucleotide codon in the mRNA with a complementary sequence called the anticodon on one of its loops. Each three-nucleotide codon is translated into one of twenty naturally occurring amino acids. There is at least one tRNA for any codon, and sometimes multiple codons code for the same amino acid. Many tRNAs are compatible with several codons. An enzyme called an aminoacyl tRNA synthetase covalently attaches the amino acid to the appropriate tRNA. Most cells have a different synthetase for each amino acid (20 or more synthetases). On the other hand, some bacteria have fewer than 20 aminoacyl tRNA synthetases, and introduce the "missing" amino acid(s) by modification of a structurally related amino acid by an aminotransferase enzyme.
The strains are small and within the elastic limit. The surfaces are continuous and non-conforming (implying that the area of contact is much smaller than the characteristic dimensions of the contacting bodies). Each body can be considered an elastic half-space. The surfaces are frictionless. Additional complications arise when some or all these assumptions are violated and such contact problems are usually called non-Hertzian.
The country's ten largest self-reported ethnic or cultural origins in 2021 were Canadian (accounting for 15.6 percent of the population), followed by English (14.7%), Irish (12.1%), Scottish (12.1%), French (11.0%), German (8.1%), Chinese (4.7%), Italian (4.3%), Indian (3.7%), and Ukrainian (3.5%). Of the 36.3 million people enumerated in 2021, approximately 25.4 million reported being "White", representing 69.8 percent of the population. The Indigenous population representing 5 percent or 1.8 million people, grew by 9.4 percent compared to the non-Indigenous population, which grew by 5.3 percent from 2016 to 2021. One out of every four Canadians or 26.5 percent of the population belonged to a non-White and non-Indigenous visible minority, the largest of which in 2021 were South Asian (2.6 million people; 7.1%), Chinese (1.7 million; 4.7%), Black (1.5 million; 4.3%), Filipinos (960,000 2.6%), Arabs (690,000; 1.9%), Latin Americans (580,000; 1.6%), Southeast Asians (390,000; 1.1%), West Asians (360,000; 1.0%), Koreans (220,000; 0.6%) and Japanese (99,000; 0.3%). Between 2011 and 2016, the visible minority population rose by 18.4 percent. In 1961, about 300,000 people, less than two percent of Canada's population, were members of visible minority groups. The 2021 census indicated that 8.3 million people, or almost one-quarter (23.0%) of the population, reported themselves as being or having been a landed immigrant or permanent resident in Canada—above the 1921 census previous record of 22.3 percent.
=== Europe === The 2026 European drug report, published by the European Union Drugs Agency, found that in a one year period prior ot the report being published that approximately 8.7% of all people in Europe aged between 15 to 64 had used cannabis during this period. This figure of 8.7% of all people in Europe is equivalent to around 25 million people. The report also found that for people aged 15 to 34 there was around 15.4 million people or roughly 15.3% who had used cannabis during this same one year period prior to the report being published. As well as this, the report found that 18% of 15 to 24 year olds reported they had used cannabis recently with there being 13% of people aged 15 to 16 who reported having used cannabis at least once in their lifetime. During this same period there was nearly 4.5 million people who reported using cannabis daily or almost daily. The 2026 European drug report also found that an estimated 850,000 people or around 0.3% of the EU adult population used opioids in 2024 with there being 860 000 people using opioids in 2023. The same report also estimated that there were 505 000 people who received opioid agonist treatment for opioid drug addiction in EU Member States in 2024 with there being 511 000 people in 2023.
Deuterium is most commonly used in hydrogen nuclear magnetic resonance spectroscopy (proton NMR) in the following way. NMR ordinarily requires compounds of interest to be analyzed as dissolved in solution. Because of deuterium's nuclear spin properties which differ from the light hydrogen usually present in organic molecules, NMR spectra of hydrogen/protium are highly differentiable from that of deuterium, and in practice deuterium is not "seen" by an NMR instrument tuned for 1H. Deuterated solvents (including heavy water, but also compounds like deuterated chloroform, CDCl3 or C2HCl3, are therefore routinely used in NMR spectroscopy, in order to allow only the light-hydrogen spectra of the compound of interest to be measured, without solvent-signal interference. Nuclear magnetic resonance spectroscopy can also be used to obtain information about the deuteron's environment in isotopically labelled samples (deuterium NMR). For example, the configuration of hydrocarbon chains in lipid bilayers can be quantified using solid state deuterium NMR with deuterium-labelled lipid molecules. Deuterium NMR spectra are especially informative in the solid state because of its relatively small quadrupole moment in comparison with those of bigger quadrupolar nuclei such as chlorine-35, for example.
Sources: en.wikipedia.org
== Indication == Trimecaine has two main application fields. The first one is local anesthesia (topical, infiltrational, topical mucosal and inhalational, spinal and Bier's intravenous). It is used in concentrations 0.4 up to 4%, in some cases (e.g. in stomatology) in mixtures with adrenaline. The other field is prophylaxis and therapy of ventriculous arrhythmia on myocardial infarction and in cardiosurgery. It is used also for prophylaxis of sympathetic reaction during tracheal intubations.
Pilot is a direct-to-consumer telehealth clinic that is owned and operated by Eucalyptus Health. The service operates in Australia and targets a male audience. Their core offerings include mental health concerns, sleep issues, erectile dysfunction, premature ejaculation, weight management and hair loss. Pilot's services are accessed through an online pre-screening questionnaire, followed by a consultation with a GP or pharmacist. Their programs may include scheduled drugs such as Viagra (Sildenafil), finasteride, Wegovy or Mounjaro alongside online coaching and diet plans. In 2026, Eucalyptus Health was acquired by the American telehealth company Hims & Hers Health, after which the Pilot brand was retired and its services relaunched under the Hims name in Australia.
Column chromatography is a chromatography method used in analytical chemistry to separate the individual components (analytes) of a mixture. The mixture is carried by a solvent (the eluent) to form the mobile phase. The mobile phase moves through a column packed with solid particles (the stationary phase). The components adsorb to the stationary phase at different rates, so they pass out of the column at different times. This separates the components. The technique is widely applicable, as many different adsorbents (normal phase, reversed phase, or otherwise) can be used with a wide range of solvents. The technique can be used on scales from micrograms up to kilograms. The main advantage of column chromatography is its cost is relatively low, and the stationary phase can be replaced after use. The latter prevents cross-contamination and stationary phase degradation due to recycling. The mobile phase moves by gravity, compressed gas, or pressurized pumps (as in high-performance liquid chromatography). Before performing column chromatography, one usually performs thin-layer chromatography on a small amount of the sample first, to see how a mixture of compounds will behave when purified by column chromatography. This allows the experimenter to optimize the combination of mobile and stationary phases for this particular sample.
Bacteria exhibit an extremely wide variety of metabolic types. The distribution of metabolic traits within a group of bacteria has traditionally been used to define their taxonomy, but these traits often do not correspond with modern genetic classifications. Bacterial metabolism is classified into nutritional groups on the basis of three major criteria: the source of energy, the electron donors used, and the source of carbon used for growth. Phototrophic bacteria derive energy from light using photosynthesis, while chemotrophic bacteria breaking down chemical compounds through oxidation. In both cases, metabolism can be driven by electron-transfer reactions in which electrons move from an electron donor to an electron acceptor. Chemotrophs are further divided by the types of compounds they use to transfer electrons. Bacteria that derive electrons from inorganic compounds such as hydrogen, carbon monoxide, or ammonia are called lithotrophs, while those that use organic compounds are called organotrophs. Still, more specifically, aerobic organisms use oxygen as the terminal electron acceptor, while anaerobic organisms use other compounds such as nitrate, sulfate, or carbon dioxide. Many bacteria, called heterotrophs, derive their carbon from other organic carbon. Others, such as cyanobacteria and some purple bacteria, are autotrophic, meaning they obtain cellular carbon by fixing carbon dioxide. In unusual circumstances, the gas methane can be used by methanotrophic bacteria as both a source of electrons and a substrate for carbon anabolism.
Sources: en.wikipedia.org
Fungaria are distinct from culture collections, which maintain living fungal isolates rather than dried reference specimens. In practice, the two are complementary, and a living culture is often linked to a dried voucher or other reference specimen preserved in a herbarium. The term refers not only to the physical collection but also to the curated metadata associated with each specimen, including information such as taxonomy, substrate, sampling location, and collection date. Because of long-standing practice in mycological nomenclature, fungaria may also include fungus-like organisms that are not classified as fungi under modern systems, such as oomycetes and slime moulds.
== History == Electron-capture dissociation (ECD) was developed in 1998 to fragment large proteins for mass spectrometric analysis. Because ECD requires a large amount of near-thermal electrons (<0.2eV), originally it was used exclusively with Fourier transform ion cyclotron resonance mass spectrometry (FTICR), the most expensive form of MS instrumentation. Less costly options such as quadrupole time-of-flight (Q-TOF), quadrupole ion trap (QIT) and linear quadrupole ion trap (QLT) instruments used the more energy-intensive collision-induced dissociation method (CID), resulting in random fragmentation of peptides and proteins. In 2004 Syka and Coon et al. announced the creation of ETD, a dissociation method similar to ECD, but using a low-cost, widely available commercial spectrometer. The first ETD experiments were run on a QLT mass spectrometer with an electrospray ionization (ESI) source.
Qing authorities established the Canton System in 1757 to regulate trade more strictly, restricting non-Russian ships to the port of Canton. Although European demand for Chinese commodities like tea, silk, and porcelain was high, Chinese interest in European manufactured goods was insignificant, so that Chinese goods could only be bought with precious metals. To reduce the trade imbalance, the British sold large amounts of Indian opium to China. Faced with a drug crisis, Qing officials pursued ever more aggressive actions to halt the opium trade.
=== Risk factors === Family history and ancestry are factors that increase the risk of beta-thalassemia. Depending on family history, if a person's parents or grandparents had beta thalassemia major or intermedia, there is a 75% (3 out of 4) probability (see inheritance chart at top of page) of the mutated gene being inherited by an offspring. Even if a child does not have symptomatic beta thalassemia they can still be a carrier, leading to an increased risk in future generations of their offspring having beta-thalassemia. Beta thalassemia occurs most often in people of Mediterranean, Middle Eastern, Southern Asian, and African ancestry.
antigen Any exogenous agent that, upon introduction into an immunocompetent organism, stimulates a response from the organism's immune system that results in the production of one or more antibodies which can bind to it specifically; in this sense the term is synonymous with immunogen. Antigens may be pure substances, mixtures of substances, or particulate matter such as cells or cell fragments. Broader definitions may include substances that can bind to a specific antibody but are not themselves immunogenic, i.e. those which are only able to stimulate antibody production when combined with a carrier.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.